Name: Oculis Holding AG (OCS) Fundamental & Financial Data
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense volatility following its first public earnings report, as investors weigh impressive revenue growth against massive capital expenditures on AI infrastructure. The community remains deeply divided, with bulls pointing to the company's long-term Starlink and launch dominance while bears express concern over a pending insider share unlock and the company's valuation relative to its current cash burn.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a volatile post-earnings reaction where investors are weighing strong data center revenue growth and upbeat 2027 guidance against concerns over rising capital expenditures and a high valuation. Community discourse remains deeply divided, with bulls pointing to the company's long-term potential in AI infrastructure while bears argue that growth expectations are already fully priced in and express skepticism regarding the company's ability to maintain its trajectory.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors react to the highly anticipated launch of its next set of BlueBird satellites, paired with recent collaborative workshops with Meta that suggest expanding commercial applications. The community is actively discussing the stock's potential to capture market share in the satellite-to-device broadband sector, focusing on the competitive positioning against other satellite providers and the strategic importance of its global mobile network operator partnerships.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant investor attention as it faces legal battles with rival Eli Lilly over weight-loss drug marketing while simultaneously navigating a high-stakes week of earnings and trial data. The community remains deeply divided, with many aggressively buying the dip in anticipation of long-term growth from the Wegovy pill, while others remain skeptical due to pipeline setbacks and intense competition.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is seeing renewed investor enthusiasm as the company continues to hit new all-time highs, fueled by an aggressive transformation plan, strong defense contracts, and expanding influence in the data center power market through its SMR technology. The community is buzzing ahead of the upcoming mid-year results, with shareholders closely tracking signs of further guidance raises, hyperscaler deals, and momentum in the aerospace aftermarket.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether its strategic plan to overhaul its digital distribution model in China represents a necessary long-term turnaround or a significant revenue risk. While some community members view the stock as a discounted value play supported by a reliable dividend, many remain bearish, pointing to persistent sales pressure and intense competition from domestic brands.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is seeing heightened investor attention as the community anticipates revenue updates and commercial milestones for Papzimeos, with significant discussion surrounding a substantial short interest and the potential for a short squeeze. Investors are actively debating the company's transition from a development-stage biotech to a commercial entity, highlighting enthusiasm for upcoming clinical data and future profitability.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is seeing heightened activity as market participants debate whether metals have bottomed following a significant price correction, with sentiment heavily influenced by macroeconomic concerns like persistent U.S. debt, cooling inflation data, and global manufacturing demand. The community is actively weighing the potential for a rebound driven by industrial demand against ongoing volatility from geopolitical tensions and interest rate expectations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors monitor escalating geopolitical tensions, central bank gold purchases, and persistent concerns over the stability of the U.S. dollar and national debt. The community remains deeply divided, with many actively debating whether current price action represents a definitive bottom and a setup for a breakout or if the asset remains trapped in a bearish consolidation phase.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing significant volatility driven by intense institutional accumulation and ongoing tension between short sellers and long-term investors betting on the company's agentic AI pivot. Market participants are closely watching for potential breakouts and accumulation patterns as sentiment pivots toward software and enterprise automation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire/ -- PomerantzLLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP...

Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky

Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, June 8, 2026 Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to...

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (Oculis or the Company) (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52...

OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations

OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations PR Newswire NEW YORK, June 2, 2026 Oculis Holding AG claimed its "most...

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) PR Newswire NEW YORK, June 1, 2026 Oculis...

OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target

Equity

Oculis said it will not pursue US Food and Drug Administration (FDA) filing for OCS-01 in diabetic macular edema following disappointing late-stage trial results.

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Oculis Holding AG

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.99
Prev Close	$11.89
Open	$12.07
Dividend Yield	0.00%
50-Day Moving Average	$13.75
Beta	0.64
Avg. Volume	346,391.36
PE Ratio	-5.60

52-Week High	$34.48
52-Week Low	$10.52
Market Capitalization	$679.75M
EPS (Annual)	-$2.28
Price to Book	2.96
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info